Skip to content

Chapter 12: Modern Applications of Microbial Genetics

Introduction

A photograph of a thermocycler; a desktop machine with a heating element and temperature display. A micrograph of oval cells; most are clear but a few are orange.

Figure 12.1 A thermal cycler (left) is used during a polymerase chain reaction (PCR). PCR amplifies the number of copies of DNA and can assist in diagnosis of infections caused by microbes that are difficult to culture, such as Chlamydia trachomatis (right). C. trachomatis causes chlamydia, the most common sexually transmitted disease in the United States, and trachoma, the world’s leading cause of preventable blindness. (credit right: modification of work by Centers for Disease Control and Prevention)

Watson and Crick’s identification of the structure of DNA in 1953 was the seminal event in the field of genetic engineering. Since the 1970s, there has been a veritable explosion in scientists’ ability to manipulate DNA in ways that have revolutionized the fields of biology, medicine, diagnostics, forensics, and industrial manufacturing. Many of the molecular tools discovered in recent decades have been produced using prokaryotic microbes. In this chapter, we will explore some of those tools, especially as they relate to applications in medicine and health care.

As an example, the thermal cycler in Figure 12.1 is used to perform a diagnostic technique called the polymerase chain reaction (PCR), which relies on DNA polymerase enzymes from thermophilic bacteria. Other molecular tools, such as restriction enzymes and plasmids obtained from microorganisms, allow scientists to insert genes from humans or other organisms into microorganisms. The microorganisms are then grown on an industrial scale to synthesize products such as insulin, vaccines, and biodegradable polymers. These are just a few of the numerous applications of microbial genetics that we will explore in this chapter.

12.1 Microbes and the Tools of Genetic Engineering

Learning Objectives

By the end of this section, you will be able to:

  • Identify tools of molecular genetics that are derived from microorganisms
  • Describe the methods used to create recombinant DNA molecules
  • Describe methods used to introduce DNA into prokaryotic cells
  • List the types of genomic libraries and describe their uses
  • Describe the methods used to introduce DNA into eukaryotic cells

Clinical Focus: Part 1

Kayla, a 24-year-old electrical engineer and running enthusiast, just moved from Arizona to New Hampshire to take a new job. On her weekends off, she loves to explore her new surroundings, going for long runs in the pine forests. In July she spent a week hiking through the mountains. In early August, Kayla developed a low fever, headache, and mild muscle aches, and she felt a bit fatigued. Not thinking much of it, she took some ibuprofen to combat her symptoms and vowed to get more rest.

  • What types of medical conditions might be responsible for Kayla’s symptoms?

Jump to the next Clinical Focus box.

The science of using living systems to benefit humankind is called biotechnology. Technically speaking, the domestication of plants and animals through farming and breeding practices is a type of biotechnology. However, in a contemporary sense, we associate biotechnology with the direct alteration of an organism’s genetics to achieve desirable traits through the process of genetic engineering. Genetic engineering involves the use of recombinant DNA technology, the process by which a DNA sequence is manipulated in vitro, thus creating recombinant DNA molecules that have new combinations of genetic material. The recombinant DNA is then introduced into a host organism. If the DNA that is introduced comes from a different species, the host organism is now considered to be transgenic.

Lydia Villa-Komaroff, working in Walter Gilbert’s lab, demonstrated the groundbreaking power of biotechnology in 1978. The group was the first to show that a transgenic bacterial strain could be used to create human insulin (Figure 12.2). The insulin gene from humans was inserted into a plasmid. This recombinant DNA plasmid was then inserted into bacteria. As a result, these transgenic microbes are able to produce and secrete human insulin. Many prokaryotes are able to acquire foreign DNA and incorporate functional genes into their own genome through “mating” with other cells (conjugation), viral infection (transduction), and taking up DNA from the environment (transformation). Recall that these mechanisms are examples of horizontal gene transfer—the transfer of genetic material between cells of the same generation.

A diagram explaining recombinant DNA technology. The insulin gene is removed from the DNA in the nucleus of a human cell. This gene is then inserted into a plasmid (a round piece of DNA). The result is a recombinant plasmid which gets inserted into a bacterial cell. The resulting transgenic bacterium is a bacterial cell with a plasmid containing the insulin gene. The recombinant bacteria divide and produce the protein coded for by the inserted gene. In this example the bacteria are producing and secreting insulin. The result is insulin in solution.

Figure 12.2 Recombinant DNA technology is the artificial recombination of DNA from two organisms. In this example, the human insulin gene is inserted into a bacterial plasmid. This recombinant plasmid can then be used to transform bacteria, which gain the ability to produce the insulin protein.

Molecular Cloning

Herbert Boyer and Stanley Cohen first demonstrated the complete molecular cloning process in 1973 when they successfully cloned genes from the African clawed frog (Xenopus laevis) into a bacterial plasmid that was then introduced into the bacterial host Escherichia coli. Molecular cloning is a set of methods used to construct recombinant DNA and incorporate it into a host organism; it makes use of a number of molecular tools that are derived from microorganisms.

Restriction Enzymes and Ligases

In recombinant DNA technology, DNA molecules are manipulated using naturally occurring enzymes derived mainly from bacteria and viruses. The creation of recombinant DNA molecules is possible due to the use of naturally occurring restriction endonucleases (restriction enzymes), bacterial enzymes produced as a protection mechanism to cut and destroy foreign cytoplasmic DNA that is most commonly a result of bacteriophage infection. Stewart Linn and Werner Arber discovered restriction enzymes in their 1960s studies of how E. coli limits bacteriophage replication on infection. Today, we use restriction enzymes extensively for cutting DNA fragments that can then be spliced into another DNA molecule to form recombinant molecules. Each restriction enzyme cuts DNA at a characteristic recognition site, a specific, usually palindromic, DNA sequence typically between four to six base pairs in length. A palindrome is a sequence of letters that reads the same forward as backward. (The word “level” is an example of a palindrome.) Palindromic DNA sequences contain the same base sequences in the 5ʹ to 3ʹ direction on one strand as in the 5ʹ to 3ʹ direction on the complementary strand. A restriction enzyme recognizes the DNA palindrome and cuts each backbone at identical positions in the palindrome. Some restriction enzymes cut to produce molecules that have complementary overhangs (sticky ends) while others cut without generating such overhangs, instead producing blunt ends (Figure 12.3).

Molecules with complementary sticky ends can easily anneal, or form hydrogen bonds between complementary bases, at their sticky ends. The annealing step allows hybridization of the single-stranded overhangs. Hybridization refers to the joining together of two complementary single strands of DNA. Blunt ends can also attach together, but less efficiently than sticky ends due to the lack of complementary overhangs facilitating the process. In either case, ligation by DNA ligase can then rejoin the two sugar-phosphate backbones of the DNA through covalent bonding, making the molecule a continuous double strand. In 1972, Paul Berg, a Stanford biochemist, was the first to produce a recombinant DNA molecule using this technique, combining the SV40 monkey virus with E. coli bacteriophage lambda to create a hybrid.

Diagrams of how restriction enzymes cut DNA. Both diagrams show a double stranded pieces of DNA that is cut. A) in sticky end cutting the DNA is cut so that there are short single stranded pieces of DNA at the cut site. In this example, the enzyme cuts the sequence GGATCC; it cuts between the two G’s. After cutting, both strands have a double stranded G/C bond, but then also have single stranded GATC. In blunt end cutting there are no single stranded ends. In this example the enzyme cuts GGCC between the G and the C.

Figure 12.3 (a) In this six-nucleotide restriction enzyme site, recognized by the enzyme BamHI, notice that the sequence reads the same in the 5ʹ to 3ʹ direction on both strands. This is known as a palindrome. The cutting of the DNA by the restriction enzyme at the sites (indicated by the black arrows) produces DNA fragments with sticky ends. Another piece of DNA cut with the same restriction enzyme could attach to one of these sticky ends, forming a recombinant DNA molecule. (b) This four-nucleotide recognition site also exhibits a palindromic sequence. The cutting of the DNA by the restriction enzyme HaeIII at the indicated sites produces DNA fragments with blunt ends. Any other piece of blunt DNA could attach to one of the blunt ends produced, forming a recombinant DNA molecule.

Plasmids

After restriction digestion, genes of interest are commonly inserted into plasmids, small pieces of typically circular, double-stranded DNA that replicate independently of the bacterial chromosome (see Unique Characteristics of Prokaryotic Cells). In recombinant DNA technology, plasmids are often used as vectors, DNA molecules that carry DNA fragments from one organism to another. Plasmids used as vectors can be genetically engineered by researchers and scientific supply companies to have specialized properties, as illustrated by the commonly used plasmid vector pUC19 (Figure 12.4). Some plasmid vectors contain genes that confer antibiotic resistance; these resistance genes allow researchers to easily find plasmid-containing colonies by plating them on media containing the corresponding antibiotic. The antibiotic kills all host cells that do not harbor the desired plasmid vector, but those that contain the vector are able to survive and grow.

Plasmid vectors used for cloning typically have a polylinker site, or multiple cloning site (MCS). A polylinker site is a short sequence containing multiple unique restriction enzyme recognition sites that are used for inserting DNA into the plasmid after restriction digestion of both the DNA and the plasmid. Having these multiple restriction enzyme recognition sites within the polylinker site makes the plasmid vector versatile, so it can be used for many different cloning experiments involving different restriction enzymes.

This polylinker site is often found within a reporter gene, another gene sequence artificially engineered into the plasmid that encodes a protein that allows for visualization of DNA insertion. The reporter gene allows a researcher to distinguish host cells that contain recombinant plasmids with cloned DNA fragments from host cells that only contain the non-recombinant plasmid vector. The most common reporter gene used in plasmid vectors is the bacterial lacZ gene encoding beta-galactosidase, an enzyme that naturally degrades lactose but can also degrade a colorless synthetic analog X-gal, thereby producing blue colonies on X-gal–containing media. The lacZ reporter gene is disabled when the recombinant DNA is spliced into the plasmid. Because the LacZ protein is not produced when the gene is disabled, X-gal is not degraded and white colonies are produced, which can then be isolated. This blue-white screening method is described later and shown in Figure 12.5. In addition to these features, some plasmids come pre-digested and with an enzyme linked to the linearized plasmid to aid in ligation after the insertion of foreign DNA fragments.

The pC19 plasmid is 2686 bp long and is circular. There are a number of arrows of various lengths moving clockwise or counterclockwise around the circle. The circle has the number 1 at the very top and at about position 225 (moving clockwise from 1) is a plylinker site (MC) that contains the following restriction enzyme sites: HidIII, PSTI, SaII, XbaI, BamHI, SmaI, EcoRI. At the beginning of the polylinker site is lacZ-alpha. At position 2500 and moving counterclockwise is the amp gene.

Figure 12.4 The artificially constructed plasmid vector pUC19 is commonly used for cloning foreign DNA. Arrows indicate the directions in which the genes are transcribed. Note the polylinker site, containing multiple unique restriction enzyme recognition sites, found within the lacZ reporter gene. Also note the ampicillin (amp) resistance gene encoded on the plasmid.

Molecular Cloning using Transformation

The most commonly used mechanism for introducing engineered plasmids into a bacterial cell is transformation, a process in which bacteria take up free DNA from their surroundings. In nature, free DNA typically comes from other lysed bacterial cells; in the laboratory, free DNA in the form of recombinant plasmids is introduced to the cell’s surroundings.

Some bacteria, such as Bacillus spp., are naturally competent, meaning they are able to take up foreign DNA. However, not all bacteria are naturally competent. In most cases, bacteria must be made artificially competent in the laboratory by increasing the permeability of the cell membrane. This can be achieved through chemical treatments that neutralize charges on the cell membrane or by exposing the bacteria to an electric field that creates microscopic pores in the cell membrane. These methods yield chemically competent or electrocompetent bacteria, respectively.

Following the transformation protocol, bacterial cells are plated onto an antibiotic-containing medium to inhibit the growth of the many host cells that were not transformed by the plasmid conferring antibiotic resistance. A technique called blue-white screening is then used for lacZ-encoding plasmid vectors such as pUC19. Blue colonies have a functional beta-galactosidase enzyme because the lacZ gene is uninterrupted, with no foreign DNA inserted into the polylinker site. These colonies typically result from the digested, linearized plasmid religating to itself. However, white colonies lack a functional beta-galactosidase enzyme, indicating the insertion of foreign DNA within the polylinker site of the plasmid vector, thus disrupting the lacZ gene. Thus, white colonies resulting from this blue-white screening contain plasmids with an insert and can be further screened to characterize the foreign DNA. To be sure the correct DNA was incorporated into the plasmid, the DNA insert can then be sequenced.

Link to Learning

View an animation of molecular cloning from the DNA Learning Center.

Check Your Understanding

  • In blue-white screening, what does a blue colony mean and why is it blue?

Molecular Cloning Using Conjugation or Transduction

The bacterial process of conjugation (see How Asexual Prokaryotes Achieve Genetic Diversity) can also be manipulated for molecular cloning. F plasmids, or fertility plasmids, are transferred between bacterial cells through the process of conjugation. Recombinant DNA can be transferred by conjugation when bacterial cells containing a recombinant F plasmid are mixed with compatible bacterial cells lacking the plasmid. F plasmids encode a surface structure called an F pilus that facilitates contact between a cell containing an F plasmid and one without an F plasmid. On contact, a cytoplasmic bridge forms between the two cells and the F-plasmid-containing cell replicates its plasmid, transferring a copy of the recombinant F plasmid to the recipient cell. Once it has received the recombinant F plasmid, the recipient cell can produce its own F pilus and facilitate transfer of the recombinant F plasmid to an additional cell. The use of conjugation to transfer recombinant F plasmids to recipient cells is another effective way to introduce recombinant DNA molecules into host cells.

Alternatively, bacteriophages can be used to introduce recombinant DNA into host bacterial cells through a manipulation of the transduction process (see How Asexual Prokaryotes Achieve Genetic Diversity). In the laboratory, DNA fragments of interest can be engineered into phagemids, which are plasmids that have phage sequences that allow them to be packaged into bacteriophages. Bacterial cells can then be infected with these bacteriophages so that the recombinant phagemids can be introduced into the bacterial cells. Depending on the type of phage, the recombinant DNA may be integrated into the host bacterial genome (lysogeny), or it may exist as a plasmid in the host’s cytoplasm.

A diagram explaining molecular cloning. Both foreign DNa and a plasmid are cut with the same restriction enzyme. The restriction site occurs only once in the plasmid in the middle of a gene for and enzyme (lacZ). The plasmid also contains an ampicillin resistang gene. The restriction enzyme leaves complementary sticky ends on the foreign DNA fragment and the plasmid. This allows the foreign DNA to be inserted into the plasmid when the sticky ends anneal. Adding DNA ligase reattaches the DNA backbones. These are recombinant plasmids. The plasmids are combined with a culture of living bacteria. Many of the bacteria do not take any plasmids into their cells. Many take plasmids that do not have the foreign DNA in them and a few take up the recombinant plasmid. The bacteria that take up the recombinant plasmid cannot make the enzyme from the gene that the fragment was inserted into (lacZ). They also carry a gene for resistance to the antibiotic ampicillin, which was on the original plasmid. To find the bacteria with the recombinant plasmid, the bacteria are grown on a plate with the antibiotic ampicillin and a substance that changes color when exposed to the enzyme produced by the lacZ gene. The ampicillin will kill any bacteria that did not take up a plasmid. The color of the substance will nto change when the gene for lacZ contains the foreign DNA insert. These are the bacteria with the recombinant plasmid that we want to grow.

Figure 12.5 The steps involved in molecular cloning using bacterial transformation are outlined in this graphic flowchart.

Check Your Understanding

  • What is the original function of a restriction enzyme?
  • What two processes are exploited to get recombinant DNA into a bacterial host cell?
  • Distinguish the uses of an antibiotic resistance gene and a reporter gene in a plasmid vector.

Creating a Genomic Library

Molecular cloning may also be used to generate a genomic library. The library is a complete (or nearly complete) copy of an organism’s genome contained as recombinant DNA plasmids engineered into unique clones of bacteria. Having such a library allows a researcher to create large quantities of each fragment by growing the bacterial host for that fragment. These fragments can be used to determine the sequence of the DNA and the function of any genes present.

One method for generating a genomic library is to ligate individual restriction enzyme-digested genomic fragments into plasmid vectors cut with the same restriction enzyme (Figure 12.6). After transformation into a bacterial host, each transformed bacterial cell takes up a single recombinant plasmid and grows into a colony of cells. All of the cells in this colony are identical clones and carry the same recombinant plasmid. The resulting library is a collection of colonies, each of which contains a fragment of the original organism’s genome, that are each separate and distinct and can each be used for further study. This makes it possible for researchers to screen these different clones to discover the one containing a gene of interest from the original organism’s genome.

A diagram showing the generation of a genomic library. The diagram begins with DNA being extracted from the organism (in this case a worm) and cut into fragments. The DNA fragments are then each inserted into a different plasmid. This produces many fragments each with a different insert from the genome. Bacteria are then transformed with these vectors. Each bacterium replicates producing colonies of clones each containing a single DNA fragment from the original organism.

Figure 12.6 The generation of a genomic library facilitates the discovery of the genomic DNA fragment that contains a gene of interest. (credit “micrograph”: modification of work by National Institutes of Health)

To construct a genomic library using larger fragments of genomic DNA, an E. coli bacteriophage, such as lambda, can be used as a host (Figure 12.7). Genomic DNA can be sheared or enzymatically digested and ligated into a pre-digested bacteriophage lambda DNA vector. Then, these recombinant phage DNA molecules can be packaged into phage particles and used to infect E. coli host cells on a plate. During infection within each cell, each recombinant phage will make many copies of itself and lyse the E. coli lawn, forming a plaque. Thus, each plaque from a phage library represents a unique recombinant phage containing a distinct genomic DNA fragment. Plaques can then be screened further to look for genes of interest. One advantage to producing a library using phages instead of plasmids is that a phage particle holds a much larger insert of foreign DNA compared with a plasmid vector, thus requiring a much smaller number of cultures to fully represent the entire genome of the original organism.

A diagram showing the production of a phage library. The cellular genome and phage genome are digested with the same restriction enzyme. The cellular DNA fragments are built into recombinant phage particles (each particle contains a different fragment of cellular DNA). E. coli is then infected with the recombinant phages. Each plaque in the bacterial lawn contains phages with a unique fragment from the original genome.

Figure 12.7 Recombinant phage DNA molecules are made by ligating digested phage particles with fragmented genomic DNA molecules. These recombinant phage DNA molecules are packaged into phage particles and allowed to infect a bacterial lawn. Each plaque represents a unique recombinant DNA molecule that can be further screened for genes of interest.

To focus on the expressed genes in an organism or even a tissue, researchers construct libraries using the organism’s messenger RNA (mRNA) rather than its genomic DNA. Whereas all cells in a single organism will have the same genomic DNA, different tissues express different genes, producing different complements of mRNA. For example, all human cells’ genomic DNA contains the gene for insulin, but only cells in the pancreas express mRNA directing the production of insulin. Because mRNA cannot be cloned directly, in the laboratory mRNA must be used as a template by the retroviral enzyme reverse transcriptase to make complementary DNA (cDNA). A cell’s full complement of mRNA can be reverse-transcribed into cDNA molecules, which can be used as a template for DNA polymerase to make double-stranded DNA copies; these fragments can subsequently be ligated into either plasmid vectors or bacteriophage to produce a cDNA library. The benefit of a cDNA library is that it contains DNA from only the expressed genes in the cell. This means that the introns, control sequences such as promoters, and DNA not destined to be translated into proteins are not represented in the library. The focus on translated sequences means that the library cannot be used to study the sequence and structure of the genome in its entirety. The construction of a cDNA genomic library is shown in Figure 12.8.

A diagram showing the generation of a cDNA library. The diagram begins with RNA being extracted from the organism (in this case a worm). Reverse transcription is then used to convert the RNA into cDNA The cDNA fragments are then each inserted into a different plasmid. This produces many fragments each with a different insert from the genome. Bacteria are then transformed with these vectors. Each bacterium replicates producing colonies of clones each containing a single cDNA fragment from the original organism.

Figure 12.8 Complementary DNA (cDNA) is made from mRNA by the retroviral enzyme reverse transcriptase, converted into double-stranded copies, and inserted into either plasmid vectors or bacteriophage, producing a cDNA library. (credit “micrograph”: modification of work by National Institutes of Health)

Check Your Understanding

  • What are the hosts for the genomic libraries described?
  • What is cDNA?

Introducing Recombinant Molecules into Eukaryotic Hosts

The use of bacterial hosts for genetic engineering laid the foundation for recombinant DNA technology; however, researchers have also had great interest in genetically engineering eukaryotic cells, particularly those of plants and animals. The introduction of recombinant DNA molecules into eukaryotic hosts is called transfection. Genetically engineered plants, called transgenic plants, are of significant interest for agricultural and pharmaceutical purposes. The first transgenic plant sold commercially was the Flavr Savr delayed-ripening tomato, which came to market in 1994. Genetically engineered livestock have also been successfully produced, resulting, for example, in pigs with increased nutritional value1 and goats that secrete pharmaceutical products in their milk.2

Electroporation

Compared to bacterial cells, eukaryotic cells tend to be less amenable as hosts for recombinant DNA molecules. Because eukaryotes are typically neither competent to take up foreign DNA nor able to maintain plasmids, transfection of eukaryotic hosts is far more challenging and requires more intrusive techniques for success. One method used for transfecting cells in cell culture is called electroporation. A brief electric pulse induces the formation of transient pores in the phospholipid bilayers of cells through which the gene can be introduced. At the same time, the electric pulse generates a short-lived positive charge on one side of the cell’s interior and a negative charge on the opposite side; the charge difference draws negatively charged DNA molecules into the cell (Figure 12.9).

A diagram showing electroporation. The first panel reads: introduce the gene into the cell. A cell with a distinct plasma membrane is shown and recombinant DNA is on the outside. The next panel reads: apply the electric pulse; pores form in the cell membrane and the gene enters. The image shows holes in the plasma membrane. Positive charges are inside the holes and negative charges are on the outside. Recombinant DNA pieces move into the cell. The final panel reads: after the electric pulse, the pores reseal and the gene remains in the cell. The diagram shows a continuous plasma membrane again and recombinant DNA both inside and outside the cell. The recombinant DNA inside the cell is labeled “introduced gene”

Figure 12.9 Electroporation is one laboratory technique used to introduce DNA into eukaryotic cells.

Microinjection

An alternative method of transfection is called microinjection. Because eukaryotic cells are typically larger than those of prokaryotes, DNA fragments can sometimes be directly injected into the cytoplasm using a glass micropipette, as shown in Figure 12.10.

A micrograph of a microinjection needle poking through the plasma membrane of a cell and into the nucleus.

Figure 12.10 Microinjection is another technique for introducing DNA into eukaryotic cells. A microinjection needle containing recombinant DNA is able to penetrate both the cell membrane and nuclear envelope.

Gene Guns

Transfecting plant cells can be even more difficult than animal cells because of their thick cell walls. One approach involves treating plant cells with enzymes to remove their cell walls, producing protoplasts. Then, a gene gun is used to shoot gold or tungsten particles coated with recombinant DNA molecules into the plant protoplasts at high speeds. Recipient protoplast cells can then recover and be used to generate new transgenic plants (Figure 12.11).

a) a diagram of a gene gun. The gun barrel points towards a plant protoplast. A pulse of helium pushes microprojections (gold or tungsten particles coated with recombinant DNA molecules) through the barrel and into the plant cell. b) a photograph of a gene gun; it is the size and shape of a hair-dryer but with a much narrower opening.

Figure 12.11 Heavy-metal particles coated with recombinant DNA are shot into plant protoplasts using a gene gun. The resulting transformed cells are allowed to recover and can be used to generate recombinant plants. (a) A schematic of a gene gun. (b) A photograph of a gene gun. (credit a, b: modification of work by JA O'Brien, SC Lummis)

Shuttle Vectors

Another method of transfecting plants involves shuttle vectors, plasmids that can move between bacterial and eukaryotic cells. The tumor-inducing (Ti) plasmids originating from the bacterium Agrobacterium tumefaciens are commonly used as shuttle vectors for incorporating genes into plants (Figure 12.12). In nature, the Ti plasmids of A. tumefaciens cause plants to develop tumors when they are transferred from bacterial cells to plant cells. Researchers have been able to manipulate these naturally occurring plasmids to remove their tumor-causing genes and insert desirable DNA fragments. The resulting recombinant Ti plasmids can be transferred into the plant genome through the natural transfer of Ti plasmids from the bacterium to the plant host. Once inside the plant host cell, the gene of interest recombines into the plant cell’s genome.

A diagram of transformation of a plant cell using the Ti plasmid. A micrograph of rod shaped cells labeled Agrobacterium tumefaciens. Plasmids are isolated from these cells. The plasmid (Ti plasmid) has a region labeled T-DNA region. A gene of interest from the cellular DNA is inseted into the T-DNA region. The transformed recombinant DNA is the returned back to A. tumefaciens. The bacterium then infects the plant cell. This inserts the gene of interest and resuts in a recombinant plant.

Figure 12.12 The Ti plasmid of Agrobacterium tumefaciens is a useful shuttle vector for the uptake of genes of interest into plant cells. The gene of interest is cloned into the Ti plasmid, which is then introduced into plant cells. The gene of interest then recombines into the plant cell’s genome, allowing for the production of transgenic plants.

Viral Vectors

Viral vectors can also be used to transfect eukaryotic cells. In fact, this method is often used in gene therapy (see Gene Therapy) to introduce healthy genes into human patients suffering from diseases that result from genetic mutations. Viral genes can be deleted and replaced with the gene to be delivered to the patient;3 the virus then infects the host cell and delivers the foreign DNA into the genome of the targeted cell. Adenoviruses are often used for this purpose because they can be grown to high titer and can infect both nondividing and dividing host cells. However, use of viral vectors for gene therapy can pose some risks for patients, as discussed in Gene Therapy.

Check Your Understanding

  • What are the methods used to introduce recombinant DNA vectors into animal cells?
  • Compare and contrast shuttle vectors and viral vectors.

12.2 Visualizing and Characterizing DNA, RNA, and Protein

Learning Objectives

By the end of this section, you will be able to:

  • Explain the use of nucleic acid probes to visualize specific DNA sequences
  • Explain the use of gel electrophoresis to separate DNA fragments
  • Explain the principle of restriction fragment length polymorphism analysis and its uses
  • Compare and contrast Southern and northern blots
  • Explain the principles and uses of microarray analysis
  • Describe the methods uses to separate and visualize protein variants
  • Explain the method and uses of polymerase chain reaction and DNA sequencing

The sequence of a DNA molecule can help us identify an organism when compared to known sequences housed in a database. The sequence can also tell us something about the function of a particular part of the DNA, such as whether it encodes a particular protein. Comparing protein signatures—the expression levels of specific arrays of proteins—between samples is an important method for evaluating cellular responses to a multitude of environmental factors and stresses. Analysis of protein signatures can reveal the identity of an organism or how a cell is responding during disease.

The DNA and proteins of interest are microscopic and typically mixed in with many other molecules including DNA or proteins irrelevant to our interests. Many techniques have been developed to isolate and characterize molecules of interest. These methods were originally developed for research purposes, but in many cases they have been simplified to the point that routine clinical use is possible. For example, many pathogens, such as the bacterium Helicobacter pylori, which causes stomach ulcers, can be detected using protein-based tests. In addition, an increasing number of highly specific and accurate DNA amplification-based identification assays can now detect pathogens such as antibiotic-resistant enteric bacteria, herpes simplex virus, varicella-zoster virus, and many others.

Molecular Analysis of DNA

In this subsection, we will outline some of the basic methods used for separating and visualizing specific fragments of DNA that are of interest to a scientist. Some of these methods do not require knowledge of the complete sequence of the DNA molecule. Before the advent of rapid DNA sequencing, these methods were the only ones available to work with DNA, but they still form the basic arsenal of tools used by molecular geneticists to study the body’s responses to microbial and other diseases.

Nucleic Acid Probing

DNA molecules are small, and the information contained in their sequence is invisible. How does a researcher isolate a particular stretch of DNA, or having isolated it, determine what organism it is from, what its sequence is, or what its function is? One method to identify the presence of a certain DNA sequence uses artificially constructed pieces of DNA called probes. Probes can be used to identify different bacterial species in the environment and many DNA probes are now available to detect pathogens clinically. For example, DNA probes are used to detect the vaginal pathogens Candida albicans, Gardnerella vaginalis, and Trichomonas vaginalis.

To screen a genomic library for a particular gene or sequence of interest, researchers must know something about that gene. If researchers have a portion of the sequence of DNA for the gene of interest, they can design a DNA probe, a single-stranded DNA fragment that is complementary to part of the gene of interest and different from other DNA sequences in the sample. The DNA probe may be synthesized chemically by commercial laboratories, or it may be created by cloning, isolating, and denaturing a DNA fragment from a living organism. In either case, the DNA probe must be labeled with a molecular tag or beacon, such as a radioactive phosphorus atom (as is used for autoradiography) or a fluorescent dye (as is used in fluorescent in situ hybridization, or FISH), so that the probe and the DNA it binds to can be seen (Figure 12.13). The DNA sample being probed must also be denatured to make it single-stranded so that the single-stranded DNA probe can anneal to the single-stranded DNA sample at locations where their sequences are complementary. While these techniques are valuable for diagnosis, their direct use on sputum and other bodily samples may be problematic due to the complex nature of these samples. DNA often must first be isolated from bodily samples through chemical extraction methods before a DNA probe can be used to identify pathogens.

A diagram of DNA probe. First a gene of interest is identified and cloned. Then single stranded probes are labeled with a molecular beacon. Finally, the DNA probe binds to complementary sequences in a DNA sample. The complementary sequences are single stranded DNA. The probe only attaches to one of the ssDNA sequences since it has the gene of interest in it

Figure 12.13 DNA probes can be used to confirm the presence of a suspected pathogen in patient samples. This diagram illustrates how a DNA probe can be used to search for a gene of interest associated with the suspected pathogen.

Clinical Focus: Part 2

The mild, flu-like symptoms that Kayla is experiencing could be caused by any number of infectious agents. In addition, several non-infectious autoimmune conditions, such as multiple sclerosis, systemic lupus erythematosus (SLE), and amyotrophic lateral sclerosis (ALS), also have symptoms that are consistent with Kayla’s early symptoms. However, over the course of several weeks, Kayla’s symptoms worsened. She began to experience joint pain in her knees, heart palpitations, and a strange limpness in her facial muscles. In addition, she suffered from a stiff neck and painful headaches. Reluctantly, she decided it was time to seek medical attention.

  • Do Kayla’s new symptoms provide any clues as to what type of infection or other medical condition she may have?
  • What tests or tools might a health-care provider use to pinpoint the pathogen causing Kayla’s symptoms?

Jump to the next Clinical Focus box. Go back to the previous Clinical Focus box.

Agarose Gel Electrophoresis

There are a number of situations in which a researcher might want to physically separate a collection of DNA fragments of different sizes. A researcher may also digest a DNA sample with a restriction enzyme to form fragments. The resulting size and fragment distribution pattern can often yield useful information about the sequence of DNA bases that can be used, much like a bar-code scan, to identify the individual or species to which the DNA belongs.

Gel electrophoresis is a technique commonly used to separate biological molecules based on size and biochemical characteristics, such as charge and polarity. Agarose gel electrophoresis is widely used to separate DNA (or RNA) of varying sizes that may be generated by restriction enzyme digestion or by other means, such as the PCR (Figure 12.14).

Due to its negatively charged backbone, DNA is strongly attracted to a positive electrode. In agarose gel electrophoresis, the gel is oriented horizontally in a buffer solution. Samples are loaded into sample wells on the side of the gel closest to the negative electrode, then drawn through the molecular sieve of the agarose matrix toward the positive electrode. The agarose matrix impedes the movement of larger molecules through the gel, whereas smaller molecules pass through more readily. Thus, the distance of migration is inversely correlated to the size of the DNA fragment, with smaller fragments traveling a longer distance through the gel. Sizes of DNA fragments within a sample can be estimated by comparison to fragments of known size in a DNA ladder also run on the same gel. To separate very large DNA fragments, such as chromosomes or viral genomes, agarose gel electrophoresis can be modified by periodically alternating the orientation of the electric field during pulsed-field gel electrophoresis (PFGE). In PFGE, smaller fragments can reorient themselves and migrate slightly faster than larger fragments and this technique can thus serve to separate very large fragments that would otherwise travel together during standard agarose gel electrophoresis. In any of these electrophoresis techniques, the locations of the DNA or RNA fragments in the gel can be detected by various methods. One common method is adding ethidium bromide, a stain that inserts into the nucleic acids at non-specific locations and can be visualized when exposed to ultraviolet light. Other stains that are safer than ethidium bromide, a potential carcinogen, are now available.

a) A diagram of the process of agarose gel electrophoresis. 1 – An agarose and buffer solution is heated and poured into a form. This result in a rectangular block with indents along one end labeled “S=sample wells”. 2 – When cooled, the agarose gel block contains small wells (S) where the sample will be place. 3 – Each sample is added to a separate well. Then the agarose gel is placed in a chamber that generates a charge across the gel. The samples are added using micropipettes. 4 – The solution within the chamber conducts the electric current generated by the chamber. The side nearest the sample well will have a negative charge; the other side will have a positive charge. 5 – DNA has a negative charge and will be drawn to the positive pole of the gel. Smaller DNA molecules will be able to travel faster through the matrix of the gel. 6 – One well will contain a DNA ladder, which has fragments of known size. This ladder is used to identify the sizes of the bands in the sample. The ladder looks like many bands in the gel; from top to bottom the sizes of the bands are – 2000 bp, 15000 bp, 1000 bp, 750 bp, 500 bp, 250 bp. The other lanes have a few bands of various sizes.

Figure 12.14 (a) The process of agarose gel electrophoresis. (b) A researcher loading samples into a gel. (c) This photograph shows a completed electrophoresis run on an agarose gel. The DNA ladder is located in lanes 1 and 9. Seven samples are located in lanes 2 through 8. The gel was stained with ethidium bromide and photographed under ultraviolet light. (credit a: modification of work by Magnus Manske; credit b: modification of work by U.S. Department of Agriculture; credit c: modification of work by James Jacob)

Restriction Fragment Length Polymorphism (RFLP) Analysis

Restriction enzyme recognition sites are short (only a few nucleotides long), sequence-specific palindromes, and may be found throughout the genome. Thus, differences in DNA sequences in the genomes of individuals will lead to differences in distribution of restriction-enzyme recognition sites that can be visualized as distinct banding patterns on a gel after agarose gel electrophoresis. Restriction fragment length polymorphism (RFLP) analysis compares DNA banding patterns of different DNA samples after restriction digestion (Figure 12.15).

RFLP analysis has many practical applications in both medicine and forensic science. For example, epidemiologists use RFLP analysis to track and identify the source of specific microorganisms implicated in outbreaks of food poisoning or certain infectious diseases. RFLP analysis can also be used on human DNA to determine inheritance patterns of chromosomes with variant genes, including those associated with heritable diseases or to establish paternity.

Forensic scientists use RFLP analysis as a form of DNA fingerprinting, which is useful for analyzing DNA obtained from crime scenes, suspects, and victims. DNA samples are collected, the numbers of copies of the sample DNA molecules are increased using PCR, and then subjected to restriction enzyme digestion and agarose gel electrophoresis to generate specific banding patterns. By comparing the banding patterns of samples collected from the crime scene against those collected from suspects or victims, investigators can definitively determine whether DNA evidence collected at the scene was left behind by suspects or victims.

A diagram of RFLP analysis. Two strands of DNA are shown; a “normal” strand and a mutated strand. The normal strand has 3 locations where the restriction enzyme MSTI cuts. The mutation on the other strand destroys one of the restriction sites. As a result, the mutated strand has one fewer bands on a gel.

Figure 12.15 RFLP analysis can be used to differentiate DNA sequences. In this example, a normal chromosome is digested into two fragments, whereas digestion of a mutated chromosome produces only one fragment. The small red arrows pointing to the two different chromosome segments show the locations of the restriction enzyme recognition sites. After digestion and agarose gel electrophoresis, the banding patterns reflect the change by showing the loss of two shorter bands and the gain of a longer band. (credit: modification of work by National Center for Biotechnology Information)

Southern Blots and Modifications

Several molecular techniques capitalize on sequence complementarity and hybridization between nucleic acids of a sample and DNA probes. Typically, probing nucleic-acid samples within a gel is unsuccessful because as the DNA probe soaks into a gel, the sample nucleic acids within the gel diffuse out. Thus, blotting techniques are commonly used to transfer nucleic acids to a thin, positively charged membrane made of nitrocellulose or nylon. In the Southern blot technique, developed by Sir Edwin Southern in 1975, DNA fragments within a sample are first separated by agarose gel electrophoresis and then transferred to a membrane through capillary action (Figure 12.16). The DNA fragments that bind to the surface of the membrane are then exposed to a specific single-stranded DNA probe labeled with a radioactive or fluorescent molecular beacon to aid in detection. Southern blots may be used to detect the presence of certain DNA sequences in a given DNA sample. Once the target DNA within the membrane is visualized, researchers can cut out the portion of the membrane containing the fragment to recover the DNA fragment of interest.

A diagram of a Southern blot. First, electrophoresis is used to separate DNA fragments by size. There can be so many fragments that they appear as a smear on the gel. Next DNA is transferred from the agarose gel to a nylon membrane. The buffer moves from the wet sponge below up through the gel and the membrane into the paper towels. It carries the DNA fragments with it until they become caught in the membrane. Finally, the membrane is based in a solution containing a probe, a short piece of DNA complementary to the sequence of interest. The probe is labeled or tagged with a fluorescent dye so that the location of DNA fragments to which it hybridizes can be visualized.

Figure 12.16 In the Southern blot technique, DNA fragments are first separated by agarose gel electrophoresis, then transferred by capillary action to a nylon membrane, which is then soaked with a DNA probe tagged with a molecular beacon for easy visualization.

Variations of the Southern blot—the dot blot, slot blot, and the spot blot—do not involve electrophoresis, but instead concentrate DNA from a sample into a small location on a membrane. After hybridization with a DNA probe, the signal intensity detected is measured, allowing the researcher to estimate the amount of target DNA present within the sample.

A colony blot is another variation of the Southern blot in which colonies representing different clones in a genomic library are transferred to a membrane by pressing the membrane onto the culture plate. The cells on the membrane are lysed and the membrane can then be probed to determine which colonies within a genomic library harbor the target gene. Because the colonies on the plate are still growing, the cells of interest can be isolated from the plate.

In the northern blot, another variation of the Southern blot, RNA (not DNA) is immobilized on the membrane and probed. Northern blots are typically used to detect the amount of mRNA made through gene expression within a tissue or organism sample.

Microarray Analysis

Another technique that capitalizes on the hybridization between complementary nucleic acid sequences is called microarray analysis. Microarray analysis is useful for the comparison of gene-expression patterns between different cell types—for example, cells infected with a virus versus uninfected cells, or cancerous cells versus healthy cells (Figure 12.17).

Typically, DNA or cDNA from an experimental sample is deposited on a glass slide alongside known DNA sequences. Each slide can hold more than 30,000 different DNA fragment types. Distinct DNA fragments (encompassing an organism’s entire genomic library) or cDNA fragments (corresponding to an organism’s full complement of expressed genes) can be individually spotted on a glass slide.

Once deposited on the slide, genomic DNA or mRNA can be isolated from the two samples for comparison. If mRNA is isolated, it is reverse-transcribed to cDNA using reverse transcriptase. Then the two samples of genomic DNA or cDNA are labeled with different fluorescent dyes (typically red and green). The labeled genomic DNA samples are then combined in equal amounts, added to the microarray chip, and allowed to hybridize to complementary spots on the microarray.

Hybridization of sample genomic DNA molecules can be monitored by measuring the intensity of fluorescence at particular spots on the microarray. Differences in the amount of hybridization between the samples can be readily observed. If only one sample’s nucleic acids hybridize to a particular spot on the microarray, then that spot will appear either green or red. However, if both samples’ nucleic acids hybridize, then the spot will appear yellow due to the combination of the red and green dyes.

Although microarray technology allows for a holistic comparison between two samples in a short time, it requires sophisticated (and expensive) detection equipment and analysis software. Because of the expense, this technology is typically limited to research settings. Researchers have used microarray analysis to study how gene expression is affected in organisms that are infected by bacteria or viruses or subjected to certain chemical treatments.

a) A diagram of a microarray. First two different cells are grown in culture – in this case cancerous and healthy cells. Then RNA is isolated from each culture. Then reverse transciptase labeling produces cDNA with either a red fluorescent probe or a green fluorescent probe. In this case the cDNA from the cancerous cells is produced using red fluorescent probes and the cDNA from healthy cells is produced using green fluorescent probes. These are then hybridized onto a microarray – which looks like a glass slide with many etchings. B) The result on a computer compares all the genes that are active in the cells. Green regions indicate genes that are only expressed in heathy cells, red regions indicate genes that are only expressed in cancerous cells, yellow regions indicate genes that are expressed in both cancerous and healthy cells, and black regions indicate genes that are not expressed in either cell type.

Figure 12.17 (a) The steps in microarray analysis are illustrated. Here, gene expression patterns are compared between cancerous cells and healthy cells. (b) Microarray information can be expressed as a heat map. Genes are shown on the left side; different samples are shown across the bottom. Genes expressed only in cancer cells are shown in varying shades of red; genes expressed only in normal cells are shown in varying shades of green. Genes that are expressed in both cancerous and normal cells are shown in yellow.

Link to Learning

Explore microchip technology at this interactive website.

Check Your Understanding

  • What does a DNA probe consist of?
  • Why is a Southern blot used after gel electrophoresis of a DNA digest?

Molecular Analysis of Proteins

In many cases it may not be desirable or possible to study DNA or RNA directly. Proteins can provide species-specific information for identification as well as important information about how and whether a cell or tissue is responding to the presence of a pathogenic microorganism. Various proteins require different methods for isolation and characterization.

Polyacrylamide Gel Electrophoresis

A variation of gel electrophoresis, called polyacrylamide gel electrophoresis (PAGE), is commonly used for separating proteins. In PAGE, the gel matrix is finer and composed of polyacrylamide instead of agarose. Additionally, PAGE is typically performed using a vertical gel apparatus (Figure 12.18). Because of the varying charges associated with amino acid side chains, PAGE can be used to separate intact proteins based on their net charges. Alternatively, proteins can be denatured and coated with a negatively charged detergent called sodium dodecyl sulfate (SDS), masking the native charges and allowing separation based on size only. PAGE can be further modified to separate proteins based on two characteristics, such as their charges at various pHs as well as their size, through the use of two-dimensional PAGE. In any of these cases, following electrophoresis, proteins are visualized through staining, commonly with either Coomassie blue or a silver stain.

a) A diagram showing a globular protein with positive and negative charges undergoing SDS treatment. SDS denatures the protein (producing a linear product) and makes them uniformly negative in charge. B) The protein samples are then placed into the wells of an SDS PAGE gel. One well is loaded with a molecular weight standard. The gel is then exposed to a power source that results in the top of the gel (near the wells) becoming negative charged and the bottom becoming positively charged. Proteins migrate through the gel from the negative to the positive sides. Small proteins travel through the gel faster than large proteins. The molecular weight standard includes fragments of known size and is used to estimate the size of sample proteins. In this example the standard has sizes of 216, 132, 78, 32 and 7. The other lanes have bands of various sizes. C) A photograph of an SDS-PAGE gel. Purple bands on a clear background.

Figure 12.18 (a) SDS is a detergent that denatures proteins and masks their native charges, making them uniformly negatively charged. (b) The process of SDS-PAGE is illustrated in these steps. (c) A photograph of an SDS-PAGE gel shows Coomassie stained bands where proteins of different size have migrated along the gel in response to the applied voltage. A size standard lane is visible on the right side of the gel. (credit b: modification of work by “GeneEd”/YouTube)

Check Your Understanding

  • On what basis are proteins separated in SDS-PAGE?

Clinical Focus: Part 3

When Kayla described her symptoms, her physician at first suspected bacterial meningitis, which is consistent with her headaches and stiff neck. However, she soon ruled this out as a possibility because meningitis typically progresses more quickly than what Kayla was experiencing. Many of her symptoms still paralleled those of amyotrophic lateral sclerosis (ALS) and systemic lupus erythematosus (SLE), and the physician also considered Lyme disease a possibility given how much time Kayla spends in the woods. Kayla did not recall any recent tick bites (the typical means by which Lyme disease is transmitted) and she did not have the typical bull’s-eye rash associated with Lyme disease (Figure 12.19). However, 20–30% of patients with Lyme disease never develop this rash, so the physician did not want to rule it out.

Kayla’s doctor ordered an MRI of her brain, a complete blood count to test for anemia, blood tests assessing liver and kidney function, and additional tests to confirm or rule out SLE or Lyme disease. Her test results were inconsistent with both SLE and ALS, and the result of the test looking for Lyme disease antibodies was “equivocal,” meaning inconclusive. Having ruled out ALS and SLE, Kayla’s doctor decided to run additional tests for Lyme disease.

  • Why would Kayla’s doctor still suspect Lyme disease even if the test results did not detect Lyme antibodies in the blood?
  • What type of molecular test might be used for the detection of blood antibodies to Lyme disease?

A photo of a bulls-eye rash; a red spot in the center and a red ring around that.

Figure 12.19 A bulls-eye rash is one of the common symptoms of Lyme diseases, but up to 30% of infected individuals never develop a rash. (credit: Centers for Disease Control and Prevention)

Jump to the next Clinical Focus box. Go back to the previous Clinical Focus box.

Amplification-Based DNA Analysis Methods

Various methods can be used for obtaining sequences of DNA, which are useful for studying disease-causing organisms. With the advent of rapid sequencing technology, our knowledge base of the entire genomes of pathogenic organisms has grown phenomenally. We start with a description of the polymerase chain reaction, which is not a sequencing method but has allowed researchers and clinicians to obtain the large quantities of DNA needed for sequencing and other studies. The polymerase chain reaction eliminates the dependence we once had on cells to make multiple copies of DNA, achieving the same result through relatively simple reactions outside the cell.

Polymerase Chain Reaction (PCR)

Most methods of DNA analysis, such as restriction enzyme digestion and agarose gel electrophoresis, or DNA sequencing require large amounts of a specific DNA fragment. In the past, large amounts of DNA were produced by growing the host cells of a genomic library. However, libraries take time and effort to prepare and DNA samples of interest often come in minute quantities. The polymerase chain reaction (PCR) permits rapid amplification in the number of copies of specific DNA sequences for further analysis (Figure 12.20). One of the most powerful techniques in molecular biology, PCR was developed in 1983 by Kary Mullis while at Cetus Corporation. PCR has specific applications in research, forensic, and clinical laboratories, including:

  • determining the sequence of nucleotides in a specific region of DNA
  • amplifying a target region of DNA for cloning into a plasmid vector
  • identifying the source of a DNA sample left at a crime scene
  • analyzing samples to determine paternity
  • comparing samples of ancient DNA with modern organisms
  • determining the presence of difficult to culture, or unculturable, microorganisms in humans or environmental samples

PCR is an in vitro laboratory technique that takes advantage of the natural process of DNA replication. The heat-stable DNA polymerase enzymes used in PCR are derived from hyperthermophilic prokaryotes. Taq DNA polymerase, commonly used in PCR, is derived from the Thermus aquaticus bacterium isolated from a hot spring in Yellowstone National Park. DNA replication requires the use of primers for the initiation of replication to have free 3ʹ-hydroxyl groups available for the addition of nucleotides by DNA polymerase. However, while primers composed of RNA are normally used in cells, DNA primers are used for PCR. DNA primers are preferable due to their stability, and DNA primers with known sequences targeting a specific DNA region can be chemically synthesized commercially. These DNA primers are functionally similar to the DNA probes used for the various hybridization techniques described earlier, binding to specific targets due to complementarity between the target DNA sequence and the primer.

PCR occurs over multiple cycles, each containing three steps: denaturation, annealing, and extension. Machines called thermal cyclers are used for PCR; these machines can be programmed to automatically cycle through the temperatures required at each step (Figure 12.1). First, double-stranded template DNA containing the target sequence is denatured at approximately 95 °C. The high temperature required to physically (rather than enzymatically) separate the DNA strands is the reason the heat-stable DNA polymerase is required. Next, the temperature is lowered to approximately 50 °C. This allows the DNA primers complementary to the ends of the target sequence to anneal (stick) to the template strands, with one primer annealing to each strand. Finally, the temperature is raised to 72 °C, the optimal temperature for the activity of the heat-stable DNA polymerase, allowing for the addition of nucleotides to the primer using the single-stranded target as a template. Each cycle doubles the number of double-stranded target DNA copies. Typically, PCR protocols include 25–40 cycles, allowing for the amplification of a single target sequence by tens of millions to over a trillion.

Natural DNA replication is designed to copy the entire genome, and initiates at one or more origin sites. Primers are constructed during replication, not before, and do not consist of a few specific sequences. PCR targets specific regions of a DNA sample using sequence-specific primers. In recent years, a variety of isothermal PCR amplification methods that circumvent the need for thermal cycling have been developed, taking advantage of accessory proteins that aid in the DNA replication process. As the development of these methods continues and their use becomes more widespread in research, forensic, and clinical labs, thermal cyclers may become obsolete.

A diagram of PCR. In cycle 1 a double stranded piece of DNA is denatured (split into 2 single strands) at 95C. Primers (short pieces of single stranded DNA) bind (anneal) to the longer strand at ~50C. DNA polymerase then binds to the primers and copies the longer strand; this is extension and occurs at 72C. This produces 2 copies of the original DNA. This repeats in cycle 2 to produce 4 copies. Cycle 3 produces 8 copies; cycle 4 produces 16; and each future cycle continues to double the number of copies.

Figure 12.20 The polymerase chain reaction (PCR) is used to produce many copies of a specific sequence of DNA.

Link to Learning

Deepen your understanding of the polymerase chain reaction by viewing this animation and working through an interactive exercise.

PCR Variations

Several later modifications to PCR further increase the utility of this technique. Reverse transcriptase PCR (RT-PCR) is used for obtaining DNA copies of a specific mRNA molecule. RT-PCR begins with the use of the reverse transcriptase enzyme to convert mRNA molecules into cDNA. That cDNA is then used as a template for traditional PCR amplification. RT-PCR can detect whether a specific gene has been expressed in a sample. Another recent application of PCR is real-time PCR, also known as quantitative PCR (qPCR). Standard PCR and RT-PCR protocols are not quantitative because any one of the reagents may become limiting before all of the cycles within the protocol are complete, and samples are only analyzed at the end. Because it is not possible to determine when in the PCR or RT-PCR protocol a given reagent has become limiting, it is not possible to know how many cycles were completed prior to this point, and thus it is not possible to determine how many original template molecules were present in the sample at the start of PCR. In qPCR, however, the use of fluorescence allows one to monitor the increase in a double-stranded template during a PCR reaction as it occurs. These kinetics data can then be used to quantify the amount of the original target sequence. The use of qPCR in recent years has further expanded the capabilities of PCR, allowing researchers to determine the number of DNA copies, and sometimes organisms, present in a sample. In clinical settings, qRT-PCR is used to determine viral load in HIV-positive patients to evaluate the effectiveness of their therapy.

DNA Sequencing

A basic sequencing technique is the chain termination method, also known as the dideoxy method or the Sanger DNA sequencing method, developed by Frederick Sanger in 1972. The chain termination method involves DNA replication of a single-stranded template with the use of a DNA primer to initiate synthesis of a complementary strand, DNA polymerase, a mix of the four regular deoxynucleotide (dNTP) monomers, and a small proportion of dideoxynucleotides (ddNTPs), each labeled with a molecular beacon. The ddNTPs are monomers missing a hydroxyl group (–OH) at the site at which another nucleotide usually attaches to form a chain (Figure 12.21). Every time a ddNTP is randomly incorporated into the growing complementary strand, it terminates the process of DNA replication for that particular strand. This results in multiple short strands of replicated DNA that are each terminated at a different point during replication. When the reaction mixture is subjected to gel electrophoresis, the multiple newly replicated DNA strands form a ladder of differing sizes. Because the ddNTPs are labeled, each band on the gel reflects the size of the DNA strand when the ddNTP terminated the reaction.

In Sanger’s day, four reactions were set up for each DNA molecule being sequenced, each reaction containing only one of the four possible ddNTPs. Each ddNTP was labeled with a radioactive phosphorus molecule. The products of the four reactions were then run in separate lanes side by side on long, narrow PAGE gels, and the bands of varying lengths were detected by autoradiography. Today, this process has been simplified with the use of ddNTPs, each labeled with a different colored fluorescent dye or fluorochrome (Figure 12.22), in one sequencing reaction containing all four possible ddNTPs for each DNA molecule being sequenced (Figure 12.23). These fluorochromes are detected by fluorescence spectroscopy. Determining the fluorescence color of each band as it passes by the detector produces the nucleotide sequence of the template strand.

A drawing of dNTPs and ddNTPs. Deoxynucleotide (dNTP) is a nucleotide with an OH at carbon #3. This is drawn as a pentagon with an O at the top. Moving counterclockwise – the next point has the word “base”, the next only has H’s, the next has an OH, and the last has 3 phosphates. Dideeoxynucleotide (ddNTP) is a nucleotide with an H at carbon #3. This is drawn as a pentagon with an O at the top. Moving counterclockwise – the next point has the word “base”, the next only has H’s, the next aso has only H’s, and the last has 3 phosphates.

Figure 12.21 A dideoxynucleotide is similar in structure to a deoxynucleotide, but is missing the 3ʹ hydroxyl group (indicated by the shaded box). When a dideoxynucleotide is incorporated into a DNA strand, DNA synthesis stops.

A diagram showing the Sanger method. A strand of DNA has the sequence GATTCAGC. Dye-labeled dideoxynucleotides are used to generate DNA fragments of different lengths. The shortest fragment ends with a red star to indicate that the ddTTP is what ended the chain. The next shortest fragment has a green star to indicate that a ddATP ended the chain. The next has a black star to indicate that a ddGTP ended the chain. The longest has a blue star to indicate that a ddCTP ended the chain. Not all of the fragments are shown in the diagram. To the right is a computer printout that does show all the fragments that would be seen in a sample. The computer printout shows a colored peak to indicate which fragment moved through the gel at that position. The first (shortest) position shows a black peak indicating a G, next is a green peak indicating an A, next is a red peak indicating a T, next are 3 green peaks indicating A’s, etc.

Figure 12.22 Frederick Sanger’s dideoxy chain termination method is illustrated, using ddNTPs tagged with fluorochromes. Using ddNTPs, a mixture of DNA fragments of every possible size, varying in length by only one nucleotide, can be generated. The DNA is separated on the basis of size and each band can be detected with a fluorescence detector.

A diagram summarizing the Sanger method. 1 – The following are added to the PCR reaction tube: DNA template, primers, DNA polymerase, dNTPs, and fluorescently labeled ddNTPs. 2 – At each base in the DNA template, either a dNTP is added and elongation continues or a ddNTP is added and elongation stops. This process results in fragments of all sizes, each with a different fluorescently labeled end nucleotide. 3 – The fragments are run through a capillary gel and detected by a laser. A computer identifies each band as it passes by a laser.

Figure 12.23 This diagram summarizes the Sanger sequencing method using fluorochrome-labeled ddNTPs and capillary gel electrophoresis.

Since 2005, automated sequencing techniques used by laboratories fall under the umbrella of next generation sequencing, which is a group of automated techniques used for rapid DNA sequencing. These methods have revolutionized the field of molecular genetics because the low-cost sequencers can generate sequences of hundreds of thousands or millions of short fragments (25 to 600 base pairs) just in one day. Although several variants of next generation sequencing technologies are made by different companies (for example, 454 Life Sciences’ pyrosequencing and Illumina’s Solexa technology), they all allow millions of bases to be sequenced quickly, making the sequencing of entire genomes relatively easy, inexpensive, and commonplace. In 454 sequencing (pyrosequencing), for example, a DNA sample is fragmented into 400–600-bp single-strand fragments, modified with the addition of DNA adapters to both ends of each fragment. Each DNA fragment is then immobilized on a bead and amplified by PCR, using primers designed to anneal to the adapters, creating a bead containing many copies of that DNA fragment. Each bead is then put into a separate well containing sequencing enzymes. To the well, each of the four nucleotides is added one after the other; when each one is incorporated, pyrophosphate is released as a byproduct of polymerization, emitting a small flash of light that is recorded by a detector. This provides the order of nucleotides incorporated as a new strand of DNA is made and is an example of synthesis sequencing. Next generation sequencers use sophisticated software to get through the cumbersome process of putting all the fragments in order. Overall, these technologies continue to advance rapidly, decreasing the cost of sequencing and increasing the availability of sequence data from a wide variety of organisms quickly.

The National Center for Biotechnology Information houses a widely used genetic sequence database called GenBank where researchers deposit genetic information for public use. Upon publication of sequence data, researchers upload it to GenBank, giving other researchers access to the information. The collaboration allows researchers to compare newly discovered or unknown sample sequence information with the vast array of sequence data that already exists.

Link to Learning

View an animation about 454 sequencing to deepen your understanding of this method.

Case in Point: Using a NAAT to Diagnose a C. difficile Infection

Javier, an 80-year-old patient with a history of heart disease, recently returned home from the hospital after undergoing an angioplasty procedure to insert a stent into a cardiac artery. To minimize the possibility of infection, Javier was administered intravenous broad-spectrum antibiotics during and shortly after his procedure. He was released four days after the procedure, but a week later, he began to experience mild abdominal cramping and watery diarrhea several times a day. He lost his appetite, became severely dehydrated, and developed a fever. He also noticed blood in his stool. Javier’s wife called the physician, who instructed her to take him to the emergency room immediately.

The hospital staff ran several tests and found that Javier’s kidney creatinine levels were elevated compared with the levels in his blood, indicating that his kidneys were not functioning well. Javier’s symptoms suggested a possible infection with Clostridioides difficile, a bacterium that is resistant to many antibiotics. The hospital collected and cultured a stool sample to look for the production of toxins A and B by C. difficile, but the results came back negative. However, the negative results were not enough to rule out a C. difficile infection because culturing of C. difficile and detection of its characteristic toxins can be difficult, particularly in some types of samples. To be safe, they proceeded with a diagnostic nucleic acid amplification test (NAAT). Currently NAATs are the clinical diagnostician’s gold standard for detecting the genetic material of a pathogen. In Javier’s case, qPCR was used to look for the gene encoding C. difficile toxin B (tcdB). When the qPCR analysis came back positive, the attending physician concluded that Javier was indeed suffering from a C. difficile infection and immediately prescribed the antibiotic vancomycin, to be administered intravenously. The antibiotic cleared the infection and Javier made a full recovery.

Because infections with C. difficile were becoming widespread in Javier’s community, his sample was further analyzed to see whether the specific strain of C. difficile could be identified. Javier’s stool sample was subjected to ribotyping and repetitive sequence-based PCR (rep-PCR) analysis. In ribotyping, a short sequence of DNA between the 16S rRNA and 23S rRNA genes is amplified and subjected to restriction digestion (Figure 12.24). This sequence varies between strains of C. difficile, so restriction enzymes will cut in different places. In rep-PCR, DNA primers designed to bind to short sequences commonly found repeated within the C. difficile genome were used for PCR. Following restriction digestion, agarose gel electrophoresis was performed in both types of analysis to examine the banding patterns that resulted from each procedure (Figure 12.25). Rep-PCR can be used to further subtype various ribotypes, increasing resolution for detecting differences between strains. The ribotype of the strain infecting Javier was found to be ribotype 27, a strain known for its increased virulence, resistance to antibiotics, and increased prevalence in the United States, Canada, Japan, and Europe.4

  • How do banding patterns differ between strains of C. difficile?
  • Why do you think laboratory tests were unable to detect toxin production directly?

A gel showing various bands of various PCR-ribotypes. The bottom lane is labeled Javier’s an matches the banding pattern from PCR-ribotype 027.

Figure 12.24 A gel showing PCR products of various Clostridioides difficile strains. Javier’s sample is shown at the bottom; note that it matches ribotype 27 in the reference set. (credit: modification of work by American Society for Microbiology)

A diagram of molecular analysis. A circular bacterial genome is shown. Primers bind to repetitive sequences found at multiple locations in the genome. These regions are amplified using PCR. Gel electrophoresis is used to identify the size of the amplified regions. Amplified fragment patters can be compared to known samples to identify strains.

Figure 12.25 Strains of infectious bacteria, such as C. difficile, can be identified by molecular analysis. PCR ribotyping is commonly used to identify particular C. difficile strains. Rep-PCR is an alternate molecular technique that is also used to identify particular C. difficile strains. (credit b: modification of work by American Society for Microbiology)

Check Your Understanding

  • How is PCR similar to the natural DNA replication process in cells? How is it different?
  • Compare RT-PCR and qPCR in terms of their respective purposes.
  • In chain-termination sequencing, how is the identity of each nucleotide in a sequence determined?

12.3 Whole Genome Methods and Pharmaceutical Applications of Genetic Engineering

Learning Objectives

By the end of this section, you will be able to:

  • Explain the uses of genome-wide comparative analyses
  • Summarize the advantages of genetically engineered pharmaceutical products

Advances in molecular biology have led to the creation of entirely new fields of science. Among these are fields that study aspects of whole genomes, collectively referred to as whole-genome methods. In this section, we’ll provide a brief overview of the whole-genome fields of genomics, transcriptomics, and proteomics.

Genomics, Transcriptomics, and Proteomics

The study and comparison of entire genomes, including the complete set of genes and their nucleotide sequence and organization, is called genomics. This field has great potential for future medical advances through the study of the human genome as well as the genomes of infectious organisms. Analysis of microbial genomes has contributed to the development of new antibiotics, diagnostic tools, vaccines, medical treatments, and environmental cleanup techniques.

The field of transcriptomics is the science of the entire collection of mRNA molecules produced by cells. Scientists compare gene expression patterns between infected and uninfected host cells, gaining important information about the cellular responses to infectious disease. Additionally, transcriptomics can be used to monitor the gene expression of virulence factors in microorganisms, aiding scientists in better understanding pathogenic processes from this viewpoint.

When genomics and transcriptomics are applied to entire microbial communities, we use the terms metagenomics and metatranscriptomics, respectively. Metagenomics and metatranscriptomics allow researchers to study genes and gene expression from a collection of multiple species, many of which may not be easily cultured or cultured at all in the laboratory. A DNA microarray (discussed in the previous section) can be used in metagenomics studies.

Another up-and-coming clinical application of genomics and transcriptomics is pharmacogenomics, also called toxicogenomics, which involves evaluating the effectiveness and safety of drugs on the basis of information from an individual’s genomic sequence. Genomic responses to drugs can be studied using experimental animals (such as laboratory rats or mice) or live cells in the laboratory before embarking on studies with humans. Changes in gene expression in the presence of a drug can sometimes be an early indicator of the potential for toxic effects. Personal genome sequence information may someday be used to prescribe medications that will be most effective and least toxic on the basis of the individual patient’s genotype.

The study of proteomics is an extension of genomics that allows scientists to study the entire complement of proteins in an organism, called the proteome. Even though all cells of a multicellular organism have the same set of genes, cells in various tissues produce different sets of proteins. Thus, the genome is constant, but the proteome varies and is dynamic within an organism. Proteomics may be used to study which proteins are expressed under various conditions within a single cell type or to compare protein expression patterns between different organisms.

The most prominent disease being studied with proteomic approaches is cancer, but this area of study is also being applied to infectious diseases. Research is currently underway to examine the feasibility of using proteomic approaches to diagnose various types of hepatitis, tuberculosis, and HIV infection, which are rather difficult to diagnose using currently available techniques.5

A recent and developing proteomic analysis relies on identifying proteins called biomarkers, whose expression is affected by the disease process. Biomarkers are currently being used to detect various forms of cancer as well as infections caused by pathogens such as Yersinia pestis and Vaccinia virus.6

Other “-omic” sciences related to genomics and proteomics include metabolomics, glycomics, and lipidomics, which focus on the complete set of small-molecule metabolites, sugars, and lipids, respectively, found within a cell. Through these various global approaches, scientists continue to collect, compile, and analyze large amounts of genetic information. This emerging field of bioinformatics can be used, among many other applications, for clues to treating diseases and understanding the workings of cells.

Additionally, researchers can use reverse genetics, a technique related to classic mutational analysis, to determine the function of specific genes. Classic methods of studying gene function involved searching for the genes responsible for a given phenotype. Reverse genetics uses the opposite approach, starting with a specific DNA sequence and attempting to determine what phenotype it produces. Alternatively, scientists can attach known genes (called reporter genes) that encode easily observable characteristics to genes of interest, and the location of expression of such genes of interest can be easily monitored. This gives the researcher important information about what the gene product might be doing or where it is located in the organism. Common reporter genes include bacterial lacZ, which encodes beta-galactosidase and whose activity can be monitored by changes in colony color in the presence of X-gal as previously described, and the gene encoding the jellyfish protein green fluorescent protein (GFP) whose activity can be visualized in colonies under ultraviolet light exposure (Figure 12.26).

a) A photograph of mice with green fluorescent regions. B) A photograph of an agar plate with green fluorescent colonies. C) A photograph of blue and white colonies on an agar plate

Figure 12.26 (a) The gene encoding green fluorescence protein is a commonly used reporter gene for monitoring gene expression patterns in organisms. Under ultraviolet light, GFP fluoresces. Here, two mice are expressing GFP, while the middle mouse is not. (b) GFP can be used as a reporter gene in bacteria as well. Here, a plate containing bacterial colonies expressing GFP is shown. (c) Blue-white screening in bacteria is accomplished through the use of the lacZ reporter gene, followed by plating of bacteria onto medium containing X-gal. Cleavage of X-gal by the LacZ enzyme results in the formation of blue colonies. (credit a: modification of work by Ingrid Moen, Charlotte Jevne, Jian Wang, Karl-Henning Kalland, Martha Chekenya, Lars A Akslen, Linda Sleire, Per Ø Enger, Rolf K Reed, Anne M Øyan, Linda EB Stuhr; credit b: modification of work by “2.5JIGEN.com”/Flickr; credit c: modification of work by American Society for Microbiology)

Check Your Understanding

  • How is genomics different from traditional genetics?
  • If you wanted to study how two different cells in the body respond to an infection, what –omics field would you apply?
  • What are the biomarkers uncovered in proteomics used for?

Clinical Focus: Resolution

Because Kayla’s symptoms were persistent and serious enough to interfere with daily activities, Kayla’s physician decided to order some laboratory tests. The physician collected samples of Kayla’s blood, cerebrospinal fluid (CSF), and synovial fluid (from one of her swollen knees) and requested PCR analysis on all three samples. The PCR tests on the CSF and synovial fluid came back positive for the presence of Borrelia burgdorferi, the bacterium that causes Lyme disease.

Kayla’s physician immediately prescribed a full course of the antibiotic doxycycline. Fortunately, Kayla recovered fully within a few weeks and did not suffer from the long-term symptoms of post-treatment Lyme disease syndrome (PTLDS), which affects 10–20% of Lyme disease patients. To prevent future infections, Kayla’s physician advised her to use insect repellant and wear protective clothing during her outdoor adventures. These measures can limit exposure to Lyme-bearing ticks, which are common in many regions of the United States during the warmer months of the year. Kayla was also advised to make a habit of examining herself for ticks after returning from outdoor activities, as prompt removal of a tick greatly reduces the chances of infection.

Lyme disease is often difficult to diagnose. B. burgdorferi is not easily cultured in the laboratory, and the initial symptoms can be very mild and resemble those of many other diseases. But left untreated, the symptoms can become quite severe and debilitating. In addition to two antibody tests, which were inconclusive in Kayla’s case, and the PCR test, a Southern blot could be used with B. burgdorferi-specific DNA probes to identify DNA from the pathogen. Sequencing of surface protein genes of Borrelia species is also being used to identify strains within the species that may be more readily transmitted to humans or cause more severe disease.

Go back to the previous Clinical Focus box.

Recombinant DNA Technology and Pharmaceutical Production

Genetic engineering has provided a way to create new pharmaceutical products called recombinant DNA pharmaceuticals. Such products include antibiotic drugs, vaccines, and hormones used to treat various diseases. Table 12.1 lists examples of recombinant DNA products and their uses.

For example, the naturally occurring antibiotic synthesis pathways of various Streptomyces spp., long known for their antibiotic production capabilities, can be modified to improve yields or to create new antibiotics through the introduction of genes encoding additional enzymes. More than 200 new antibiotics have been generated through the targeted inactivation of genes and the novel combination of antibiotic synthesis genes in antibiotic-producing Streptomyces hosts.7

Genetic engineering is also used to manufacture subunit vaccines, which are safer than other vaccines because they contain only a single antigenic molecule and lack any part of the genome of the pathogen (see Vaccines). For example, a vaccine for hepatitis B is created by inserting a gene encoding a hepatitis B surface protein into a yeast; the yeast then produces this protein, which the human immune system recognizes as an antigen. The hepatitis B antigen is purified from yeast cultures and administered to patients as a vaccine. Even though the vaccine does not contain the hepatitis B virus, the presence of the antigenic protein stimulates the immune system to produce antibodies that will protect the patient against the virus in the event of exposure.8 9

Genetic engineering has also been important in the production of other therapeutic proteins, such as insulin, interferons, and human growth hormone, to treat a variety of human medical conditions. For example, at one time, it was possible to treat diabetes only by giving patients pig insulin, which had supply limitations and caused allergic reactions due to small differences between the proteins expressed in human and pig insulin. Villa-Komaroff's and the Gilbert team's groundbreaking methods changed that. After they demonstrated the process for producing the hormone, the FDA approved the resulting synthetic insulin for human use. And since 1982, recombinant DNA technology has been used to produce large-scale quantities of human insulin using E. coli in a relatively inexpensive process that yields a more consistently effective pharmaceutical product. Scientists have also genetically engineered E. coli capable of producing human growth hormone (HGH), which is used to treat growth disorders in children and certain other disorders in adults. The HGH gene was cloned from a cDNA library and inserted into E. coli cells by cloning it into a bacterial vector. Eventually, genetic engineering will be used to produce DNA vaccines and various gene therapies, as well as customized medicines for fighting cancer and other diseases.

Table 12.1

Some Genetically Engineered Pharmaceutical Products and Applications
Recombinant DNA Product Application
Atrial natriuretic peptide Treatment of heart disease (e.g., congestive heart failure), kidney disease, high blood pressure
DNase Treatment of viscous lung secretions in cystic fibrosis
Erythropoietin Treatment of severe anemia with kidney damage
Factor VIII Treatment of hemophilia
Hepatitis B vaccine Prevention of hepatitis B infection
Human growth hormone Treatment of growth hormone deficiency, Turner’s syndrome, burns
Human insulin Treatment of diabetes
Interferons Treatment of multiple sclerosis, various cancers (e.g., melanoma), viral infections (e.g., Hepatitis B and C)
Tetracenomycins Used as antibiotics
Tissue plasminogen activator Treatment of pulmonary embolism in ischemic stroke, myocardial infarction

Check Your Understanding

  • What bacterium has been genetically engineered to produce human insulin for the treatment of diabetes?
  • Explain how microorganisms can be engineered to produce vaccines.

RNA Interference Technology

In Structure and Function of RNA, we described the function of mRNA, rRNA, and tRNA. In addition to these types of RNA, cells also produce several types of small noncoding RNA molecules that are involved in the regulation of gene expression. These include antisense RNA molecules, which are complementary to regions of specific mRNA molecules found in both prokaryotes and eukaryotic cells. Non-coding RNA molecules play a major role in RNA interference (RNAi), a natural regulatory mechanism by which mRNA molecules are prevented from guiding the synthesis of proteins. RNA interference of specific genes results from the base pairing of short, single-stranded antisense RNA molecules to regions within complementary mRNA molecules, preventing protein synthesis. Cells use RNA interference to protect themselves from viral invasion, which may introduce double-stranded RNA molecules as part of the viral replication process (Figure 12.27).

A eukaryotic cell transcribes a region of DNA into mrNA. Antisense mRNA then binds to the this mRNA to produce a double stranded region. This region is not translated (which means that ribosomes do not bind to the mRNA to produce proteins).

Figure 12.27 Cells like the eukaryotic cell shown in this diagram commonly make small antisense RNA molecules with sequences complementary to specific mRNA molecules. When an antisense RNA molecule is bound to an mRNA molecule, the mRNA can no longer be used to direct protein synthesis. (credit: modification of work by Robinson R)

Researchers are currently developing techniques to mimic the natural process of RNA interference as a way to treat viral infections in eukaryotic cells. RNA interference technology involves using small interfering RNAs (siRNAs) or microRNAs (miRNAs) (Figure 12.28). siRNAs are completely complementary to the mRNA transcript of a specific gene of interest while miRNAs are mostly complementary. These double-stranded RNAs are bound to DICER, an endonuclease that cleaves the RNA into short molecules (approximately 20 nucleotides long). The RNAs are then bound to RNA-induced silencing complex (RISC), a ribonucleoprotein. The siRNA-RISC complex binds to mRNA and cleaves it. For miRNA, only one of the two strands binds to RISC. The miRNA-RISC complex then binds to mRNA, inhibiting translation. If the miRNA is completely complementary to the target gene, then the mRNA can be cleaved. Taken together, these mechanisms are known as gene silencing.

Double stranded RNA can be produced from DNA in the nucleus. Dicer than cuts this dsRNA into either miRNA or siRNA. miRNA is an imperfect match and only one strand is usually incorporated into RISC. This blocks translation but the mRNA is stable. The RISC is stuck on the target. The siRNA has a perfect match and is incorporated into RISC. This triggers mRNA cleavage.

Figure 12.28 This diagram illustrates the process of using siRNA or miRNA in a eukaryotic cell to silence genes involved in the pathogenesis of various diseases. (credit: modification of work by National Center for Biotechnology Information)

12.4 Gene Therapy

Learning Objectives

By the end of this section, you will be able to:

  • Summarize the mechanisms, risks, and potential benefits of gene therapy
  • Identify ethical issues involving gene therapy and the regulatory agencies that provide oversight for clinical trials
  • Compare somatic-cell and germ-line gene therapy

Many types of genetic engineering have yielded clear benefits with few apparent risks. Few would question, for example, the value of our now abundant supply of human insulin produced by genetically engineered bacteria. However, many emerging applications of genetic engineering are much more controversial, often because their potential benefits are pitted against significant risks, real or perceived. This is certainly the case for gene therapy, a clinical application of genetic engineering that may one day provide a cure for many diseases but is still largely an experimental approach to treatment.

Mechanisms and Risks of Gene Therapy

Human diseases that result from genetic mutations are often difficult to treat with drugs or other traditional forms of therapy because the signs and symptoms of disease result from abnormalities in a patient’s genome. For example, a patient may have a genetic mutation that prevents the expression of a specific protein required for the normal function of a particular cell type. This is the case in patients with Severe Combined Immunodeficiency (SCID), a genetic disease that impairs the function of certain white blood cells essential to the immune system.

Gene therapy attempts to correct genetic abnormalities by introducing a nonmutated, functional gene into the patient’s genome. The nonmutated gene encodes a functional protein that the patient would otherwise be unable to produce. Viral vectors such as adenovirus are sometimes used to introduce the functional gene; part of the viral genome is removed and replaced with the desired gene (Figure 12.29). More advanced forms of gene therapy attempt to correct the mutation at the original site in the genome, such as is the case with treatment of SCID.

A diagram of gene therapy. A virus vector contains modified viral DNA that includes an inserted gene. First the vector binds to the cell membrane. The vector is then packaged in a vesicle. The vesicle then breaks down releasing the vector. The cell now makes protein using the new gene.

Figure 12.29 Gene therapy using an adenovirus vector can be used to treat or cure certain genetic diseases in which a patient has a defective gene. (credit: modification of work by National Institutes of Health)

So far, gene therapies have proven relatively ineffective, with the possible exceptions of treatments for cystic fibrosis and adenosine deaminase deficiency, a type of SCID. Other trials have shown the clear hazards of attempting genetic manipulation in complex multicellular organisms like humans. In some patients, the use of an adenovirus vector can trigger an unanticipated inflammatory response from the immune system, which may lead to organ failure. Moreover, because viruses can often target multiple cell types, the virus vector may infect cells not targeted for the therapy, damaging these other cells and possibly leading to illnesses such as cancer. Another potential risk is that the modified virus could revert to being infectious and cause disease in the patient. Lastly, there is a risk that the inserted gene could unintentionally inactivate another important gene in the patient’s genome, disrupting normal cell cycling and possibly leading to tumor formation and cancer. Because gene therapy involves so many risks, candidates for gene therapy need to be fully informed of these risks before providing informed consent to undergo the therapy.

Case in Point: Gene Therapy Gone Wrong

The risks of gene therapy were realized in the 1999 case of Jesse Gelsinger, an 18-year-old patient who received gene therapy as part of a clinical trial at the University of Pennsylvania. Jesse received gene therapy for a condition called ornithine transcarbamylase (OTC) deficiency, which leads to ammonia accumulation in the blood due to deficient ammonia processing. Four days after the treatment, Jesse died after a massive immune response to the adenovirus vector.10

Until that point, researchers had not really considered an immune response to the vector to be a legitimate risk, but on investigation, it appears that the researchers had some evidence suggesting that this was a possible outcome. Prior to Jesse’s treatment, several other human patients had suffered side effects of the treatment, and three monkeys used in a trial had died as a result of inflammation and clotting disorders. Despite this information, it appears that neither Jesse nor his family were made aware of these outcomes when they consented to the therapy. Jesse’s death was the first patient death due to a gene therapy treatment and resulted in the immediate halting of the clinical trial in which he was involved, the subsequent halting of all other gene therapy trials at the University of Pennsylvania, and the investigation of all other gene therapy trials in the United States. As a result, the regulation and oversight of gene therapy overall was reexamined, resulting in new regulatory protocols that are still in place today.

Check Your Understanding

  • Explain how gene therapy works in theory.
  • Identify some risks of gene therapy.

Oversight of Gene Therapy

Presently, there is significant oversight of gene therapy clinical trials. At the federal level, three agencies regulate gene therapy in parallel: the Food and Drug Administration (FDA), the Office of Human Research Protection (OHRP), and the Recombinant DNA Advisory Committee (RAC) at the National Institutes of Health (NIH). Along with several local agencies, these federal agencies interact with the institutional review board to ensure that protocols are in place to protect patient safety during clinical trials. Compliance with these protocols is enforced mostly on the local level in cooperation with the federal agencies. Gene therapies are currently under the most extensive federal and local review compared to other types of therapies, which are more typically only under the review of the FDA. Some researchers believe that these extensive regulations actually inhibit progress in gene therapy research. In 2013, the Institute of Medicine (now the National Academy of Medicine) called upon the NIH to relax its review of gene therapy trials in most cases.11 However, ensuring patient safety continues to be of utmost concern.

Ethical Concerns

Beyond the health risks of gene therapy, the ability to genetically modify humans poses a number of ethical issues related to the limits of such “therapy.” While current research is focused on gene therapy for genetic diseases, scientists might one day apply these methods to manipulate other genetic traits not perceived as desirable. This raises questions such as:

  • Which genetic traits are worthy of being “corrected”?
  • Should gene therapy be used for cosmetic reasons or to enhance human abilities?
  • Should genetic manipulation be used to impart desirable traits to the unborn?
  • Is everyone entitled to gene therapy, or could the cost of gene therapy create new forms of social inequality?
  • Who should be responsible for regulating and policing inappropriate use of gene therapies?

The ability to alter reproductive cells using gene therapy could also generate new ethical dilemmas. To date, the various types of gene therapies have been targeted to somatic cells, the non-reproductive cells within the body. Because somatic cell traits are not inherited, any genetic changes accomplished by somatic-cell gene therapy would not be passed on to offspring. However, should scientists successfully introduce new genes to germ cells (eggs or sperm), the resulting traits could be passed on to offspring. This approach, called germ-line gene therapy, could potentially be used to combat heritable diseases, but it could also lead to unintended consequences for future generations. Moreover, there is the question of informed consent, because those impacted by germ-line gene therapy are unborn and therefore unable to choose whether they receive the therapy. For these reasons, the U.S. government does not currently fund research projects investigating germ-line gene therapies in humans.

Eye on Ethics: Risky Gene Therapies

While there are currently no gene therapies on the market in the United States, many are in the pipeline and it is likely that some will eventually be approved. With recent advances in gene therapies targeting p53, a gene whose somatic cell mutations have been implicated in over 50% of human cancers,12 cancer treatments through gene therapies could become much more widespread once they reach the commercial market.

Bringing any new therapy to market poses ethical questions that pit the expected benefits against the risks. How quickly should new therapies be brought to the market? How can we ensure that new therapies have been sufficiently tested for safety and effectiveness before they are marketed to the public? The process by which new therapies are developed and approved complicates such questions, as those involved in the approval process are often under significant pressure to get a new therapy approved even in the face of significant risks.

To receive FDA approval for a new therapy, researchers must collect significant laboratory data from animal trials and submit an Investigational New Drug (IND) application to the FDA’s Center for Drug Evaluation and Research (CDER). Following a 30-day waiting period during which the FDA reviews the IND, clinical trials involving human subjects may begin. If the FDA perceives a problem prior to or during the clinical trial, the FDA can order a “clinical hold” until any problems are addressed. During clinical trials, researchers collect and analyze data on the therapy’s effectiveness and safety, including any side effects observed. Once the therapy meets FDA standards for effectiveness and safety, the developers can submit a New Drug Application (NDA) that details how the therapy will be manufactured, packaged, monitored, and administered.

Because new gene therapies are frequently the result of many years (even decades) of laboratory and clinical research, they require a significant financial investment. By the time a therapy has reached the clinical trials stage, the financial stakes are high for pharmaceutical companies and their shareholders. This creates potential conflicts of interest that can sometimes affect the objective judgment of researchers, their funders, and even trial participants. The Jesse Gelsinger case (see Case in Point: Gene Therapy Gone Wrong) is a classic example. Faced with a life-threatening disease and no reasonable treatments available, it is easy to see why a patient might be eager to participate in a clinical trial no matter the risks. It is also easy to see how a researcher might view the short-term risks for a small group of study participants as a small price to pay for the potential benefits of a game-changing new treatment.

Gelsinger’s death led to increased scrutiny of gene therapy, and subsequent negative outcomes of gene therapy have resulted in the temporary halting of clinical trials pending further investigation. For example, when children in France treated with gene therapy for SCID began to develop leukemia several years after treatment, the FDA temporarily stopped clinical trials of similar types of gene therapy occurring in the United States.13 Cases like these highlight the need for researchers and health professionals not only to value human well-being and patients’ rights over profitability, but also to maintain scientific objectivity when evaluating the risks and benefits of new therapies.

Check Your Understanding

  • Why is gene therapy research so tightly regulated?
  • What is the main ethical concern associated with germ-line gene therapy?

Chapter Review

Key Concepts and Summary

12.1 Microbes and the Tools of Genetic Engineering

  • Biotechology is the science of utilizing living systems to benefit humankind. In recent years, the ability to directly alter an organism’s genome through geneticengineering has been made possible due to advances in recombinant DNA technology, which allows researchers to create recombinant DNA molecules with new combinations of genetic material.
  • Molecular cloning involves methods used to construct recombinant DNA and facilitate their replication in host organisms. These methods include the use of restriction enzymes (to cut both foreign DNA and plasmid vectors), ligation (to paste fragments of DNA together), and the introduction of recombinant DNA into a host organism (often bacteria).
  • Blue-white screening allows selection of bacterial transformants that contain recombinant plasmids using the phenotype of a reporter gene that is disabled by insertion of the DNA fragment.
  • Genomic libraries can be made by cloning genomic fragments from one organism into plasmid vectors or into bacteriophage.
  • cDNA libraries can be generated to represent the mRNA molecules expressed in a cell at a given point.
  • Transfection of eukaryotic hosts can be achieved through various methods using electroporation, gene guns, microinjection, shuttle vectors, and viral vectors.

12.2 Visualizing and Characterizing DNA, RNA, and Protein

  • Finding a gene of interest within a sample requires the use of a single-stranded DNA probe labeled with a molecular beacon (typically radioactivity or fluorescence) that can hybridize with a complementary single-stranded nucleic acid in the sample.
  • Agarose gel electrophoresis allows for the separation of DNA molecules based on size.
  • Restriction fragment length polymorphism(RFLP) analysis allows for the visualization by agarose gel electrophoresis of distinct variants of a DNA sequence caused by differences in restriction sites.
  • Southern blot analysis allows researchers to find a particular DNA sequence within a sample whereas northern blot analysis allows researchers to detect a particular mRNA sequence expressed in a sample.
  • Microarray technology is a nucleic acid hybridization technique that allows for the examination of many thousands of genes at once to find differences in genes or gene expression patterns between two samples of genomic DNA or cDNA,
  • Polyacrylamide gel electrophoresis (PAGE) allows for the separation of proteins by size, especially if native protein charges are masked through pretreatment with SDS.
  • Polymerase chain reaction allows for the rapid amplification of a specific DNA sequence. Variations of PCR can be used to detect mRNA expression (reverse transcriptase PCR) or to quantify a particular sequence in the original sample (real-time PCR).
  • Although the development of Sanger DNA sequencing was revolutionary, advances in next generation sequencing allow for the rapid and inexpensive sequencing of the genomes of many organisms, accelerating the volume of new sequence data.

12.3 Whole Genome Methods and Pharmaceutical Applications of Genetic Engineering

  • The science of genomics allows researchers to study organisms on a holistic level and has many applications of medical relevance.
  • Transcriptomics and proteomics allow researchers to compare gene expression patterns between different cells and shows great promise in better understanding global responses to various conditions.
  • The various –omics technologies complement each other and together provide a more complete picture of an organism’s or microbial community’s (metagenomics) state.
  • The analysis required for large data sets produced through genomics, transcriptomics, and proteomics has led to the emergence of bioinformatics.
  • Reporter genes encoding easily observable characteristics are commonly used to track gene expression patterns of genes of unknown function.
  • The use of recombinant DNA technology has revolutionized the pharmaceutical industry, allowing for the rapid production of high-quality recombinant DNA pharmaceuticals used to treat a wide variety of human conditions.
  • RNA interference technology has great promise as a method of treating viral infections by silencing the expression of specific genes

12.4 Gene Therapy

  • While gene therapy shows great promise for the treatment of genetic diseases, there are also significant risks involved.
  • There is considerable federal and local regulation of the development of gene therapies by pharmaceutical companies for use in humans.
  • Before gene therapy use can increase dramatically, there are many ethical issues that need to be addressed by the medical and research communities, politicians, and society at large.

Multiple Choice

12.1 Microbes and the Tools of Genetic Engineering

1. Which of the following is required for repairing the phosphodiester backbone of DNA during molecular cloning?

  1. cDNA
  2. reverse transcriptase
  3. restriction enzymes
  4. DNA ligase
Answer

D

2. All of the following are processes used to introduce DNA molecules into bacterial cells except:

  1. transformation
  2. transduction
  3. transcription
  4. conjugation
Answer

C

3. The enzyme that uses RNA as a template to produce a DNA copy is called:

  1. a restriction enzyme
  2. DNA ligase
  3. reverse transcriptase
  4. DNA polymerase
Answer

C

4. In blue-white screening, what do blue colonies represent?

  1. cells that have not taken up the plasmid vector
  2. cells with recombinant plasmids containing a new insert
  3. cells containing empty plasmid vectors
  4. cells with a non-functional lacZ gene
Answer

C

5. The Ti plasmid is used for introducing genes into:

  1. animal cells
  2. plant cells
  3. bacteriophages
  4. E. coli cells
Answer

B

12.2 Visualizing and Characterizing DNA, RNA, and Protein

6. Which technique is used to separate protein fragments based on size?

  1. polyacrylamide gel electrophoresis
  2. Southern blot
  3. agarose gel electrophoresis
  4. polymerase chain reaction
Answer

A

7. Which technique uses restriction enzyme digestion followed by agarose gel electrophoresis to generate a banding pattern for comparison to another sample processed in the same way?

  1. qPCR
  2. RT-PCR
  3. RFLP
  4. 454 sequencing
Answer

C

8. All of the following techniques involve hybridization between single-stranded nucleic acid molecules except:

  1. Southern blot analysis
  2. RFLP analysis
  3. northern blot analysis
  4. microarray analysis
Answer

B

12.3 Whole Genome Methods and Pharmaceutical Applications of Genetic Engineering

9. The science of studying the entire collection of mRNA molecules produced by cells, allowing scientists to monitor differences in gene expression patterns between cells, is called:

  1. genomics
  2. transcriptomics
  3. proteomics
  4. pharmacogenomics
Answer

B

10. The science of studying genomic fragments from microbial communities, allowing researchers to study genes from a collection of multiple species, is called:

  1. pharmacogenomics
  2. transcriptomics
  3. metagenomics
  4. proteomics
Answer

C

11. The insulin produced by recombinant DNA technology is

  1. a combination of E. coli and human insulin.
  2. identical to human insulin produced in the pancreas.
  3. cheaper but less effective than pig insulin for treating diabetes.
  4. engineered to be more effective than human insulin.
Answer

B

12.4 Gene Therapy

12. At what point can the FDA halt the development or use of gene therapy?

  1. on submission of an IND application
  2. during clinical trials
  3. after manufacturing and marketing of the approved therapy
  4. all of the answers are correct
Answer

D

True/False

12.1 Microbes and the Tools of Genetic Engineering

13. Recombination is a process not usually observed in nature.

Answer

false

14. It is generally easier to introduce recombinant DNA into prokaryotic cells than into eukaryotic cells.

Answer

true

12.2 Visualizing and Characterizing DNA, RNA, and Protein

15. In agarose gel electrophoresis, DNA will be attracted to the negative electrode.

Answer

false

12.3 Whole Genome Methods and Pharmaceutical Applications of Genetic Engineering

16. RNA interference does not influence the sequence of genomic DNA.

Answer

true

Fill in the Blank

12.1 Microbes and the Tools of Genetic Engineering

17. The process of introducing DNA molecules into eukaryotic cells is called ________.

Answer

transfection

12.2 Visualizing and Characterizing DNA, RNA, and Protein

18. The __________ blot technique is used to find an RNA fragment within a sample that is complementary to a DNA probe.

Answer

northern

19. The PCR step during which the double-stranded template molecule becomes single-stranded is called _____________.

Answer

denaturation

20. The sequencing method involving the incorporation of ddNTPs is called __________.

Answer

Sanger sequencing, dideoxy method, or chain termination method

12.3 Whole Genome Methods and Pharmaceutical Applications of Genetic Engineering

21. The application of genomics to evaluate the effectiveness and safety of drugs on the basis of information from an individual’s genomic sequence is called ____________.

Answer

pharmacogenomics or toxicogenomics

22. A gene whose expression can be easily visualized and monitored is called a ________.

Answer

reporter gene

12.4 Gene Therapy

23. _____________ is a common viral vector used in gene therapy for introducing a new gene into a specifically targeted cell type.

Answer

Adenovirus

Short answer

12.1 Microbes and the Tools of Genetic Engineering

24. Name three elements incorporated into a plasmid vector for efficient cloning.

25. When would a scientist want to generate a cDNA library instead of a genomic library?

26. What is one advantage of generating a genomic library using phages instead of plasmids?

12.2 Visualizing and Characterizing DNA, RNA, and Protein

27. Why is it important that a DNA probe be labeled with a molecular beacon?

28. When separating proteins strictly by size, why is exposure to SDS first required?

29. Why must the DNA polymerase used during PCR be heat-stable?

12.3 Whole Genome Methods and Pharmaceutical Applications of Genetic Engineering

30. If all cellular proteins are encoded by the cell’s genes, what information does proteomics provide that genomics cannot?

12.4 Gene Therapy

31. Briefly describe the risks associated with somatic cell gene therapy.

Critical Thinking

12.1 Microbes and the Tools of Genetic Engineering

32. Is biotechnology always associated with genetic engineering? Explain your answer.

33. Which is more efficient: blunt-end cloning or sticky-end cloning? Why?

12.2 Visualizing and Characterizing DNA, RNA, and Protein

34. Suppose you are working in a molecular biology laboratory and are having difficulty performing the PCR successfully. You decide to double-check the PCR protocol programmed into the thermal cycler and discover that the annealing temperature was programmed to be 65 °C instead of 50 °C, as you had intended. What effects would this mistake have on the PCR reaction? Refer to Figure 12.20.

35. What is the advantage of microarray analysis over northern blot analysis in monitoring changes in gene expression?

36. What is the difference between reverse transcriptase PCR (RT-PCR) and real-time quantitative PCR (qPCR)?

12.3 Whole Genome Methods and Pharmaceutical Applications of Genetic Engineering

37. What are some advantages of cloning human genes into bacteria to treat human diseases caused by specific protein deficiencies?

12.4 Gene Therapy

38. Compare the ethical issues involved in the use of somatic cell gene therapy and germ-line gene therapy.


Adapted from Microbiology by OpenStax, licensed under CC BY 4.0. Access the original for free at openstax.org. Changes: converted to the web reading format of The Open Book Project.


  1. Liangxue Lai, Jing X. Kang, Rongfeng Li, Jingdong Wang, William T. Witt, Hwan Yul Yong, Yanhong Hao et al. “Generation of Cloned Transgenic Pigs Rich in Omega-3 Fatty Acids.” Nature Biotechnology 24 no. 4 (2006): 435–436. ↩

  2. Raylene Ramos Moura, Luciana Magalhães Melo, and Vicente José de Figueirêdo Freitas. “Production of Recombinant Proteins in Milk of Transgenic and Non-Transgenic Goats.” Brazilian Archives of Biology and Technology 54 no. 5 (2011): 927–938. ↩

  3. William S.M. Wold and Karoly Toth. “Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy.” Current Gene Therapy 13 no. 6 (2013): 421. ↩

  4. Patrizia Spigaglia, Fabrizio Barbanti, Anna Maria Dionisi, and Paola Mastrantonio. “Clostridioides difficile Isolates Resistant to Fluoroquinolones in Italy: Emergence of PCR Ribotype 018.” Journal of Clinical Microbiology 48 no. 8 (2010): 2892–2896. ↩

  5. E.O. List, D.E. Berryman, B. Bower, L. Sackmann-Sala, E. Gosney, J. Ding, S. Okada, and J.J. Kopchick. “The Use of Proteomics to Study Infectious Diseases.” Infectious Disorders-Drug Targets (Formerly Current Drug Targets-Infectious Disorders) 8 no. 1 (2008): 31–45. ↩

  6. Mohan Natesan, and Robert G. Ulrich. “Protein Microarrays and Biomarkers of Infectious Disease.” International Journal of Molecular Sciences 11 no. 12 (2010): 5165–5183. ↩

  7. Jose-Luis Adrio and Arnold L. Demain. “Recombinant Organisms for Production of Industrial Products.” Bioengineered Bugs 1 no. 2 (2010): 116–131. ↩

  8. U.S. Department of Health and Human Services. “Types of Vaccines.” 2013. http://www.vaccines.gov/more_info/types/#subunit. Accessed May 27, 2016. ↩

  9. The Internet Drug List. Recombivax. 2015. http://www.rxlist.com/recombivax-drug.htm. Accessed May 27, 2016. ↩

  10. Barbara Sibbald. “Death but One Unintended Consequence of Gene-Therapy Trial.” Canadian Medical Association Journal 164 no. 11 (2001): 1612–1612. ↩

  11. Kerry Grens. “Report: Ease Gene Therapy Reviews.” The Scientist, December 9, 2013. http://www.the-scientist.com/?articles.view/articleNo/38577/title/Report--Ease-Gene-Therapy-Reviews/. Accessed May 27, 2016. ↩

  12. Zhen Wang and Yi Sun. “Targeting p53 for Novel Anticancer Therapy.” Translational Oncology 3, no. 1 (2010): 1–12. ↩

  13. Erika Check. “Gene Therapy: A Tragic Setback.” Nature 420 no. 6912 (2002): 116–118. ↩